Researchers find experimental drug may prevent or slow vision loss in people with diabetes
May 30th 2023Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.
Read More
ARVO 2023: Research on epigenetic reprogramming to reverse aging and restore function to RGCs
April 29th 2023Our onsite team spoke with Bruce Ksander, PhD, at the 2023 ARVO annual meeting, where he discussed his presentation about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells.
Read More
Nanoscope Therapeutics Inc. presented key data at the ARVO 2023 annual meeting regarding their from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010, which has received both orphan drug and fast track designations from the FDA.
Read More
D-4517.2 is a novel precision nanomedicine that inhibits neovascularization by targeting activated microglia and hypertrophic retinal pigment cells, cells responsible for the increased vascularization associated with neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Read More